These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23485543)

  • 1. Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia.
    Skalova S; Cerna L; Bayer M; Kutilek S; Konrad M; Schlingmann KP
    Iran J Kidney Dis; 2013 Mar; 7(2):160-4. PubMed ID: 23485543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for treatment of severe idiopathic infantile hypercalcemia.
    Hooman N
    Iran J Kidney Dis; 2013 Mar; 7(2):79-81. PubMed ID: 23485530
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene.
    Fencl F; Bláhová K; Schlingmann KP; Konrad M; Seeman T
    Eur J Pediatr; 2013 Jan; 172(1):45-9. PubMed ID: 23001465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations.
    Figueres ML; Linglart A; Bienaime F; Allain-Launay E; Roussey-Kessler G; Ryckewaert A; Kottler ML; Hourmant M
    Am J Kidney Dis; 2015 Jan; 65(1):122-6. PubMed ID: 25446019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pamidronate treatment of hypercalcemia caused by vitamin D toxicity.
    Chatterjee M; Speiser PW
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1241-8. PubMed ID: 18183797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia.
    Dauber A; Nguyen TT; Sochett E; Cole DE; Horst R; Abrams SA; Carpenter TO; Hirschhorn JN
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E268-74. PubMed ID: 22112808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biallelic mutations in CYP24A1 or SLC34A1 as a cause of infantile idiopathic hypercalcemia (IIH) with vitamin D hypersensitivity: molecular study of 11 historical IIH cases.
    Pronicka E; Ciara E; Halat P; Janiec A; Wójcik M; Rowińska E; Rokicki D; Płudowski P; Wojciechowska E; Wierzbicka A; Książyk JB; Jacoszek A; Konrad M; Schlingmann KP; Litwin M
    J Appl Genet; 2017 Aug; 58(3):349-353. PubMed ID: 28470390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis.
    Alos N; Eugène D; Fillion M; Powell J; Kokta V; Chabot G
    Horm Res; 2006; 65(6):289-94. PubMed ID: 16612105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH)
    Kaufmann M; Morse N; Molloy BJ; Cooper DP; Schlingmann KP; Molin A; Kottler ML; Gallagher JC; Armas L; Jones G
    J Bone Miner Res; 2017 Jul; 32(7):1589-1596. PubMed ID: 28304097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lightwood syndrome revisited with a novel mutation in CYP24 and vitamin D supplement recommendations.
    Castanet M; Mallet E; Kottler ML
    J Pediatr; 2013 Oct; 163(4):1208-10. PubMed ID: 23768816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presymptomatic diagnosis of CYP24A1-related infantile idiopathic hypercalcemia: A case report.
    Mirea AM; Pop RM; Căinap SS; Trifa AP
    Eur J Med Genet; 2020 Dec; 63(12):104100. PubMed ID: 33186763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: A cross-sectional study.
    Cools M; Goemaere S; Baetens D; Raes A; Desloovere A; Kaufman JM; De Schepper J; Jans I; Vanderschueren D; Billen J; De Baere E; Fiers T; Bouillon R
    Bone; 2015 Dec; 81():89-96. PubMed ID: 26117226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
    Tagiyev A; Demirbilek H; Tavil B; Buyukyilmaz G; Gumruk F; Cetin M
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):232-4. PubMed ID: 26907650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of a recurrent 10.9 kb CYP24A1 deletion in Idiopathic Infantile Hypercalcemia.
    Molin A; Nowoczyn M; Coudray N; Ballandone C; Abéguilé G; Mittre H; Richard N; Eckart P; Castanet M; Kottler ML
    Eur J Med Genet; 2019 Nov; 62(11):103577. PubMed ID: 30423445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational Spectrum of CYP24A1 Gene in a Cohort of Italian Patients with Idiopathic Infantile Hypercalcemia.
    Gigante M; Santangelo L; Diella S; Caridi G; Argentiero L; D''Alessandro MM; Martino M; Stea ED; Ardissino G; Carbone V; Pepe S; Scrutinio D; Maringhini S; Ghiggeri GM; Grandaliano G; Giordano M; Gesualdo L
    Nephron; 2016; 133(3):193-204. PubMed ID: 27394135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe hypercalcemia associated with Williams syndrome successfully treated with pamidronate infusion therapy.
    Sangun O; Dundar BN; Erdogan E
    J Pediatr Endocrinol Metab; 2011; 24(1-2):69-70. PubMed ID: 21528818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in CYP24A1 and idiopathic infantile hypercalcemia.
    Schlingmann KP; Kaufmann M; Weber S; Irwin A; Goos C; John U; Misselwitz J; Klaus G; Kuwertz-Bröking E; Fehrenbach H; Wingen AM; Güran T; Hoenderop JG; Bindels RJ; Prosser DE; Jones G; Konrad M
    N Engl J Med; 2011 Aug; 365(5):410-21. PubMed ID: 21675912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duplex high resolution melting analysis (dHRMA) to detect two hot spot CYP24A1 pathogenic variants (PVs) associated to idiopathic infantile hypercalcemia (IIH).
    De Bonis M; De Paolis E; Onori ME; Mazzuccato G; Gatto A; Ferrara P; Ferraro PM; Urbani A; Minucci A
    Mol Biol Rep; 2021 Apr; 48(4):3303-3311. PubMed ID: 33864587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild Idiopathic Infantile Hypercalcemia-Part 1: Biochemical and Genetic Findings.
    Lenherr-Taube N; Young EJ; Furman M; Elia Y; Assor E; Chitayat D; Uster T; Kirwin S; Robbins K; Vinette KMB; Daneman A; Marshall CR; Collins C; Thummel K; Sochett E; Levine MA
    J Clin Endocrinol Metab; 2021 Sep; 106(10):2915-2937. PubMed ID: 34125233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe infantile hypercalcemia associated with Williams syndrome successfully treated with intravenously administered pamidronate.
    Cagle AP; Waguespack SG; Buckingham BA; Shankar RR; Dimeglio LA
    Pediatrics; 2004 Oct; 114(4):1091-5. PubMed ID: 15466114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.